Concord Biotech
 | This article needs additional citations for verification. (June 2019) |
 | |
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 2000 |
| Founder | Sudhir Vaid |
| Headquarters | , India |
Area served | Worldwide |
Key people |
|
| Products | Biologics Small molecules Active ingredient |
| Revenue |  ₹1,016 crore (US$130 million) (FY24)[1] |
| ₹466 crore (US$58 million) (FY24)[1] | |
| ₹308 crore (US$39 million) (FY24)[1] | |
Number of employees | 1,180 (2022)[2] |
| Website | www |
Concord Biotech Limited (CBL) is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation based biopharmaceutical active pharmaceutical ingredients (APIs) sold worldwide.[3]
Concord was founded in 2000 by Sudhir Vaid. It manufactures over 30 products across therapy segments such as immunosuppressant, oncology, antifungal, and antibacterial.[4] It was the first company in India and the second in the world to develop an anti-immuno suppressant tacrolimus.[5] Its manufacturing facility in Ahmedabad is approved by global regulatory bodies including Food and Drug Administration (US) and Good manufacturing practice (EU).[6]
Quadria Capital acquired a 20% stake in Concord Biotech in 2016.[7][8][9] Rakesh Jhunjhunwala's Rare Enterprises holds 24% stake in Concord.[10][11][12]
See also
References
- ^ a b c "Concord Biotech consolidated net profit rises 3.86% in the March 2024 quarter". Business Standard. Retrieved 24 May 2024.
- ^ "Annual Report : FY21-22" (PDF). Concord Biotech. Retrieved 17 December 2022.
- ^ "Jhunjhunwala backed Concord Biotech sets IPO price band at Rs 705-741". Moneycontrol. 31 July 2023. Retrieved 31 July 2023.
- ^ "Quadria Capital consortium acquires stake in 'Concord Biotech'". Business Standard. Retrieved 5 July 2016.
- ^ "Concord Biotech eyes 5-fold growth by '06". Business Standard. Retrieved 28 February 2013.
- ^ "Concord Biotech mulling new unit". Business Standard. Retrieved 5 February 2013.
- ^ "Quadria Cap concludes Rs 475.31 crore investment in Concord". The Economic Times. Retrieved 5 July 2016.
- ^ "Healthcare-focussed PE firm Quadria lines up $9.8-million fund for India". Business Line. Retrieved 13 October 2016.
- ^ "Healthcare sector sees 88 funding deals worth $397 million in 2016". The Economic Times. Retrieved 19 September 2016.
- ^ "Rakesh Jhunjhunwala to give up Concord Biotech stake, eyes Rs 500 cr". The Economic Times. Retrieved 16 March 2015.
- ^ "Domestic pharmaceutical players eye Bharat Serums acquisition". The Economic Times. Retrieved 30 August 2018.
- ^ "Quadria to invest in Concord Biotech". Mint. Retrieved 18 January 2016.